These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103. Methylation-mediated silencing of protein kinase C zeta induces apoptosis avoidance through ATM/CHK2 inactivation in dedifferentiated chondrosarcoma. Shimada E; Matsumoto Y; Nakagawa M; Susuki Y; Endo M; Setsu N; Fujiwara T; Iida K; Nabeshima A; Yahiro K; Kimura A; Hirose T; Kanahori M; Oyama R; Oda Y; Nakashima Y Br J Cancer; 2022 May; 126(9):1289-1300. PubMed ID: 35017658 [TBL] [Abstract][Full Text] [Related]
104. Distinct IDH1/2-associated Methylation Profile and Enrichment of Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116 [TBL] [Abstract][Full Text] [Related]
105. TCF-1 participates in the occurrence of dedifferentiated chondrosarcoma. Xu X; Tang X; Guo W; Yang K; Ren T Tumour Biol; 2016 Oct; 37(10):14129-14140. PubMed ID: 27522523 [TBL] [Abstract][Full Text] [Related]
106. Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin. Lv J; Qian Y; Ni X; Xu X; Dong X Tumour Biol; 2017 Mar; 39(3):1010428317694307. PubMed ID: 28347251 [TBL] [Abstract][Full Text] [Related]
107. Rotavirus activates a noncanonical ATM-Chk2 branch of DNA damage response during infection to positively regulate viroplasm dynamics. Sarkar R; Patra U; Lo M; Mukherjee A; Biswas A; Chawla-Sarkar M Cell Microbiol; 2020 Mar; 22(3):e13149. PubMed ID: 31845505 [TBL] [Abstract][Full Text] [Related]
108. Different expression of Sox9 and Runx2 between chondrosarcoma and dedifferentiated chondrosarcoma cell line. Tang X; Lu X; Guo W; Ren T; Zhao H; Zhao F; Tang G Eur J Cancer Prev; 2010 Nov; 19(6):466-71. PubMed ID: 20683191 [TBL] [Abstract][Full Text] [Related]
109. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Duffaud F; Italiano A; Bompas E; Rios M; Penel N; Mir O; Piperno-Neumann S; Chevreau C; Delcambre C; Bertucci F; Boudou-Rouquette P; Cancel M; Perrin C; Saada-Bouzid E; Monard L; Schiffler C; Chaigneau L; Hervieu A; Collard O; Bouvier C; Vidal V; Chabaud S; Blay JY; Eur J Cancer; 2021 Jun; 150():108-118. PubMed ID: 33895682 [TBL] [Abstract][Full Text] [Related]
110. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nicolle R; Ayadi M; Gomez-Brouchet A; Armenoult L; Banneau G; Elarouci N; Tallegas M; Decouvelaere AV; Aubert S; Rédini F; Marie B; Labit-Bouvier C; Reina N; Karanian M; le Nail LR; Anract P; Gouin F; Larousserie F; de Reyniès A; de Pinieux G Nat Commun; 2019 Oct; 10(1):4622. PubMed ID: 31604924 [TBL] [Abstract][Full Text] [Related]
111. The Dual Roles of the Atypical Protein Kinase Cs in Cancer. Reina-Campos M; Diaz-Meco MT; Moscat J Cancer Cell; 2019 Sep; 36(3):218-235. PubMed ID: 31474570 [TBL] [Abstract][Full Text] [Related]